MDB Capital/Media/Reports

This whitepaper provides an in-depth analysis of the patent landscape in fields of MASH (Metabolic-Associated Steatohepatitis) biomarkers and Point of Care (PoC) kits. By examining key patent applications and identifying the leading players in the field, this paper offers valuable insights into the technological advancements, competitive dynamics, and potential opportunities within this space.

Introduction
The fields of MASH (Metabolic-Associated Steatohepatitis) biomarkers and Point of Care (PoC) kits for MASH diagnostics are experiencing rapid growth and innovation. This surge is driven by the recent Rezdiffra approval and the increasing demand from physicians to detect and monitor treatment responses to the first approved MASH drug. This growth is further reflected in the consistent patenting activity, signifying intense research and development efforts by biotechnology and pharmaceutical companies, academic institutions, and healthcare technology firms.

Read full report here or download PDF below.

MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.

 PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.

 All patent portfolio data and analysis in this report are based on publicly available information as of June 2024, sourced through PatentVest, our proprietary global patent database. While every effort has been made to ensure accuracy and completeness, the findings may not reflect unpublished, pending, or confidential filings. Companies may hold additional IP assets that are not yet publicly disclosed. This report should be considered a snapshot, not a definitive account, of current IP positions.

 Information in this message from employees of MDB Capital or an affiliated company is based upon information that is believed to be reliable. However, neither MDB Capital nor its affiliates warrant its completeness, accuracy or adequacy.

 This message is provided for information purposes only. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. MDB Capital does not make any representations or warranties concerning the past or future performance of any financial instrument. Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.

 This message and any attachments are intended only for the use of the addressee and may contain confidential, proprietary and/or privileged information. If you are not the intended recipient, any review, use, distribution, dissemination or copying of this email is prohibited. If you have received this email in error, please notify the sender by replying to this message and delete this email immediately.

 To view a listing of all our important disclosures, please visit www.mdb.com/disclosures. For additional information, please visit www.mdb.com or contact us at 945.262.9010.